[go: up one dir, main page]

EP3793542A4 - Compositions à base de cannabinoïdes enrichies en terpène(s) et leurs utilisations dans le traitement de pathologies infectieuses - Google Patents

Compositions à base de cannabinoïdes enrichies en terpène(s) et leurs utilisations dans le traitement de pathologies infectieuses Download PDF

Info

Publication number
EP3793542A4
EP3793542A4 EP19803400.1A EP19803400A EP3793542A4 EP 3793542 A4 EP3793542 A4 EP 3793542A4 EP 19803400 A EP19803400 A EP 19803400A EP 3793542 A4 EP3793542 A4 EP 3793542A4
Authority
EP
European Patent Office
Prior art keywords
terpene
treatment
infectious conditions
cannabinoid compositions
enriched cannabinoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19803400.1A
Other languages
German (de)
English (en)
Other versions
EP3793542A2 (fr
Inventor
Noa Raz
Aharon M. Eyal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Buzzelet Development and Technologies Ltd
Original Assignee
Buzzelet Development and Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Buzzelet Development and Technologies Ltd filed Critical Buzzelet Development and Technologies Ltd
Publication of EP3793542A2 publication Critical patent/EP3793542A2/fr
Publication of EP3793542A4 publication Critical patent/EP3793542A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A61K31/125—Camphor; Nuclear substituted derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP19803400.1A 2018-05-14 2019-05-13 Compositions à base de cannabinoïdes enrichies en terpène(s) et leurs utilisations dans le traitement de pathologies infectieuses Pending EP3793542A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862670870P 2018-05-14 2018-05-14
US201962833671P 2019-04-13 2019-04-13
PCT/IB2019/053954 WO2019220324A2 (fr) 2018-05-14 2019-05-13 Compositions à base de cannabinoïdes enrichies en terpène(s) et leurs utilisations dans le traitement de pathologies infectieuses

Publications (2)

Publication Number Publication Date
EP3793542A2 EP3793542A2 (fr) 2021-03-24
EP3793542A4 true EP3793542A4 (fr) 2022-03-30

Family

ID=68540697

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19803400.1A Pending EP3793542A4 (fr) 2018-05-14 2019-05-13 Compositions à base de cannabinoïdes enrichies en terpène(s) et leurs utilisations dans le traitement de pathologies infectieuses

Country Status (3)

Country Link
US (1) US20210059978A1 (fr)
EP (1) EP3793542A4 (fr)
WO (1) WO2019220324A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3057647A1 (fr) * 2019-10-03 2021-04-03 Vinsan Therapeutics Inc. Formulations topiques, instillations, trousses et methodes de traitement de blessures tegumentaires, et utilisations connexes
CN111235045A (zh) * 2020-01-19 2020-06-05 天津大学 异源合成β-香树脂醇和齐墩果酸的重组解脂耶氏酵母及构建方法
US20230255985A1 (en) * 2020-06-09 2023-08-17 Credo Science, Llc Methods and compositions for treatment of head lice
IL301908A (en) * 2020-10-04 2023-06-01 The State Of Israel Ministry Of Agriculture & Rural Development Agricultural Res Organization Aro Vo Cannabinoidal compositions for the treatment of disease
WO2024257801A1 (fr) * 2023-06-13 2024-12-19 デンカ株式会社 Adjuvant et composition associée

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008107879A1 (fr) * 2007-03-05 2008-09-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Dérivés cannabinoïdes atypiques et leur utilisation en tant qu'agents anti-inflammatoires
DE102007046086A1 (de) * 2007-09-26 2009-04-09 Heinz Prof. Dr. Letzel Pflanzenextrakt aus THC-armen Cannabis zur Behandlung von Erkrankungen
US20120231083A1 (en) * 2010-11-18 2012-09-13 The Board Of Trustees Of The University Of Illinois Sustained release cannabinoid medicaments
US8758826B2 (en) * 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods
EP2934512B1 (fr) * 2012-12-18 2021-11-24 Kotzker Consulting LLC Utilisation de cannabinoïdes et de terpènes pour le traitement d'une toxicité d'organophosphate et de carbamate
PL3062606T3 (pl) * 2013-10-29 2019-09-30 Biotech Institute, Llc Hodowla, produkcja, przeróbka oraz zastosowanie specjalnych konopi
US20160279073A1 (en) * 2013-10-31 2016-09-29 Full Spectrum Laboratories, Ltd. Terpene and cannabinoid formulations
US20160022627A2 (en) * 2014-04-18 2016-01-28 Mary's Medicinals LLC Transdermal cannabinoid patch
WO2016014699A1 (fr) * 2014-07-22 2016-01-28 Ralco Nutrition, Inc. Compositions antivirales et procédés
US10172786B2 (en) * 2014-12-16 2019-01-08 Axim Biotechnologies, Inc. Oral care composition comprising cannabinoids
CA3017696A1 (fr) * 2016-03-16 2017-09-21 Buzzelet Development And Technologies Ltd Composition de cannabinoides enrichie en terpene
US20170281701A1 (en) * 2016-04-05 2017-10-05 Catherine Ket Wah Kan Formulation for the Nebulization of Oil Based Substances Suitable for Use with a Vibrating Mesh Nebulizer
SG11201900596XA (en) * 2016-08-03 2019-02-27 Zelda Therapeutics Operations Pty Ltd Cannabis composition
CN110709069A (zh) * 2017-03-30 2020-01-17 奥海能量公益公司 用于增强健康的方法和组合物
CA3071497A1 (fr) * 2017-08-13 2019-02-21 Buzzelet Development And Technologies Ltd Composition de cannabinoide enrichie en terpene et procede de traitement

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Advances in Pharmacology", vol. 80, 1 January 2017, ACADEMIC PRESS, US, ISSN: 1054-3589, article RUSSO ETHAN B. ET AL: "Cannabis Pharmacology: The Usual Suspects and a Few Promising Leads", pages: 67 - 134, XP055892124, DOI: 10.1016/bs.apha.2017.03.004 *
LEWIS MARK ET AL: "Pharmacological Foundations of Cannabis Chemovars", PLANTA MEDICA, vol. 84, no. 04, 21 November 2017 (2017-11-21), DE, pages 225 - 233, XP055802596, ISSN: 0032-0943, Retrieved from the Internet <URL:https://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-0043-122240.pdf> DOI: 10.1055/s-0043-122240 *
RUSSO ETHAN B: "Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects", BJP, 31 August 2011 (2011-08-31), pages 1 - 21, XP055892117, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165946/pdf/bph0163-1344.pdf> [retrieved on 20220215] *

Also Published As

Publication number Publication date
EP3793542A2 (fr) 2021-03-24
US20210059978A1 (en) 2021-03-04
WO2019220324A3 (fr) 2020-01-02
WO2019220324A2 (fr) 2019-11-21

Similar Documents

Publication Publication Date Title
EP3846846A4 (fr) Compositions et procédés pour le traitement d&#39;infections virales
EP3716767A4 (fr) Méthodes et compositions pour le traitement de maladies rares
EP3793542A4 (fr) Compositions à base de cannabinoïdes enrichies en terpène(s) et leurs utilisations dans le traitement de pathologies infectieuses
EP3633034A4 (fr) PROTÉINE Cas9 MODIFIÉE, ET APPLICATION ASSOCIÉE
EP3790861A4 (fr) Compositions sénolytiques et utilisations associées
EP3860619A4 (fr) Compositions et méthodes pour le traitement d&#39;infections pathogènes dans des plantes
EP3946315A4 (fr) Compositions de cannabinoïdes et leur utilisation
EP3829307A4 (fr) Compositions de bismuth-thiol et méthodes d&#39;utilisation
EP3808357A4 (fr) Composition et ses applications
EP3818085A4 (fr) Compositions et leurs utilisations pour traiter une maladie ou un état pathologique
EP3681540A4 (fr) Agents à base de chlorotoxine et leurs utilisations
EP3806845A4 (fr) Composition de cannabinoïdes et méthodes de traitement utilisant cette dernière
EP3897615A4 (fr) Compositions de cannabis et méthodes
EP3891242A4 (fr) Compositions adhésives à polyesters comprenant 2, 2, 4, 4-tétraalkyl-1, 3-cyclobutanediol et leurs procédés de fabrication
IL273988A (en) Compounds of cannabidiol and chitosan, and methods for their use
EP3931200A4 (fr) Nouveaux mogrosides et leurs utilisations
EP3452015A4 (fr) Compositions et méthodes pour le traitement de l&#39;inflammation ou de l&#39;infection de l&#39;oeil
EP3463347A4 (fr) Dérivés de triazole benzamide et compositions et procédés de traitement associés
EP3706767A4 (fr) Compositions et méthodes pour le traitement d&#39;une allergie
EP3703691A4 (fr) Compositions pharmaceutiques pour lutter contre et/ou réduire la progression de la myopie
EP3749354A4 (fr) Nouvelle composition et son utilisation
EP3635324A4 (fr) Compositions de congélation inverse et utilisation de celles-ci
EP3793612A4 (fr) Compositions comprenant des molécules de liaison à la pcsk9 et méthodes d&#39;utilisation
EP3668836A4 (fr) Compositions destinées au traitement de l&#39; il sec et leurs procédés d&#39;utilisation
EP3606951A4 (fr) Compositions d&#39;alpha-1-antitrypsine mutantes et leur utilisation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201214

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20220225

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 33/06 20060101ALI20220221BHEP

Ipc: A61P 31/12 20060101ALI20220221BHEP

Ipc: A61P 31/04 20060101ALI20220221BHEP

Ipc: A61P 29/00 20060101ALI20220221BHEP

Ipc: A61P 25/04 20060101ALI20220221BHEP

Ipc: A61P 31/00 20060101ALI20220221BHEP

Ipc: A61K 36/185 20060101ALI20220221BHEP

Ipc: A61K 31/352 20060101AFI20220221BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20250127